Preventive Medications in Pediatric Migraine: A Network Meta-Analysis

Area of Science:

• Neurology
• Pharmacology
• Clinical Trials

Background:

• Pediatric migraine significantly affects children's quality of life and academic performance.
• Effective pharmacological prophylaxis is crucial for managing pediatric migraine.

Purpose of the Study:

• To conduct a network meta-analysis evaluating the efficacy and safety of oral pharmacological treatments for pediatric migraine prophylaxis.
• To compare various interventions against each other and placebo.

Main Methods:

• Searched PubMed, Embase, and SCOPUS for randomized clinical trials up to September 2023.
• Included 45 trials with 3771 participants, extracting data per PRISMA guidelines.
• Analyzed primary outcomes (migraine frequency) and secondary outcomes (responder rate, duration, intensity, disability, adverse events).

Main Results:

• Topiramate and pregabalin significantly reduced migraine frequency compared to placebo.
• Several other drugs (flunarizine, levetiracetam, riboflavin, cinnarizine, amitriptyline) also showed reduced frequency, but require more studies.
• Significant improvements were noted for responder rates and headache intensity with certain drugs, but not for quality of life or attack duration.
• Adverse events were higher with amitriptyline, topiramate, and valproate.

Conclusions:

• Topiramate and pregabalin demonstrate efficacy in reducing pediatric migraine frequency and intensity.
• Current treatments do not improve quality of life or attack duration, indicating a need for novel therapeutic strategies.
• Further research into combination therapies, including vitamins, is warranted for comprehensive pediatric migraine management.